Observational studyBMJ open2026
Positive predictive value of mpox diagnoses in French emergency departments: a retrospective validation study using the OSCOUR network.
Observational study in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to evaluate the positive predictive value (PPV) of clinical mpox diagnoses in the French OSCOUR emergency department (ED) surveillance network in the early phase of the 2022 epidemic.
designRetrospective observational study.
settingEDs across France contributing to the OSCOUR network (over 700 participating EDs covering 97% of national visits).
participantsA total of 531 mpox-related ED visits, identified through clinical diagnoses coded using International Classification of Diseases, 10th Revision (ICD-10), were extracted from the OSCOUR database between May and July 2022. After investigation, we found the accompanying PCR test results for 243 of these cases and they were included in the PPV analysis. OUTCOME MEASURES: The primary outcome was the PPV of clinical mpox diagnoses compared with PCR-confirmed mpox cases. Secondary outcomes were PPV stratified by age, geographical location (Greater Paris vs another region), time of admission, sex and time period.
resultsOf the 243 cases with available PCR test results, 175 were confirmed positive and 68 were negative. The overall PPV was 0.72 (95% CI: 0.66 to 0.77). Differences in PPV were observed by sex (F: 0.14 (0.05-0.35); M: 0.77 (0.72-0.82)), age (Less than 30: 0.67 (0.56-0.76), 30-49: 0.83 (0.76-0.88), 50+: 0.33 (0.18-0.53)), geographical location (Greater Paris: 0.77 (0.70-0.82) and other regions: 0.59 (0.46-0.70)).
conclusionOur findings show that overall, the OSCOUR network has a PPV of 0.72 for identifying mpox cases based on ICD-10 coding during the early phase of the 2022 epidemic. These results suggest that this system can be useful when tracking the beginning of emerging health threats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.